Replies to post #117828 on Biotech Values

[DewDiligence]

ABT ReadMeFirst

[Added “Investors Overplay JAK Threat to Abbott's Humira,”
the most important recent article on the company, IMO.]


Finances, outlook, and valuation
#msg-61383188 Investors overplay JAK threat to Humira
#msg-61658082 ABT is undervalued, says Barron’s
#msg-59334527 4Q10 financial results
#msg-60102300 ABT hikes dividend for 39th consecutive year!
#msg-32844386 New $5B buyback authorization
#msg-51791410 Which are the most attractive Big Pharma? (Jun 2010)
#msg-35632310 Feb 2009 feature in Barron’s


Acquisitions (in reverse chronological order)
#msg-50436738 Piramal
#msg-50473238 India’s fake drugs are a real problem
#msg-50438863 Further rationale for Piramal deal
#msg-50022514 Zydus Cadila
#msg-47606240 Facet Biotech
#msg-43510907 Anti-NGF mAb for pain
#msg-41922225 Solvay Pharmaceuticals
#msg-41374735 Evalve
#msg-41143330 Visiogen
#msg-34762429 Advanced Medical Optics (AGN spin-off)
#msg-34244326 Ibis Biosciences (former ISIS subsidiary)
#msg-14553895 Kos Pharmaceuticals
#msg-10772808 Guidant vascular business (PR)
#msg-9314269 Guidant vascular business (commentary)
#msg-34774636 Jan 2009 feature in WSJ


Cholesterol franchise
#msg-43586320 Niaspan bests Zetia in ARBITER 6–HALT study
#msg-38554134 Niaspan lowers level of lipoprotein
#msg-51992958 Revisiting the ACCORD study
#msg-47808752 TriCor fails to impress in ACCORD study (PR)
#msg-47808450 TriCor fails to impress in ACCORD study (Reuters)
#msg-58066714 ABT/AZN drop Certriad program
#msg-33503193 TriLipix statin-combo data
#msg-34203456 FDA approves TriLipix
#msg-26869744 FDA approves Simcor
#msg-28510348 Heart disease: Not about cholesterol?
#msg-43674310 What’s up with MRK’s Cordaptive?


Drug business (general)
#msg-61383188 Investors overplay JAK threat to Humira
#msg-56946507 Phase-2b Bardoxolone data in CKD
#msg-54747777 ABT licenses Reata’s Bardoxolone
#msg-58794717 ABT withdraws BLA/MAA for Briakinumab
#msg-50509176 Daclizumab starts phase-3 in MS
#msg-51343858 ABT licenses NBIX’s Elagolix for endometriosis
#msg-57504180 Phase-2 Elotuzumab Data in MM
#msg-52406597 Nuke-sparing HIV program (Kaletra+Isentress)
#msg-50894737 Oncology pipeline
#msg-61757048 Multi-pronged program in HCV
#msg-29106939 ADHD program
#msg-56345210 Humira continues on monster pace
#msg-39417561 Size and segments of US market for RA
#msg-26156472 FDA approves Humira for plaque psoriasis


Xience and Absorb stents
#msg-54841998 Xience continues to best Taxus in SPIRIT IV
#msg-41731638 Xience blows away Taxus at three years in SPIRIT III
#msg-54842212 Xience crushes Taxus Liberté at 2 years
#msg-38097301 Xience shines in hard-to-treat subgroups
#msg-55763971 DES notes from 3Q10 CC
#msg-39762286 DES US/global market shares (2Q09)
#msg-30452522 FDA approves Xience
#msg-38985789 EU approves Xience Prime
#msg-45262545 Xience approved in Japan
#msg-41529862 Xience approved in China

#msg-61503095 WSJ profiles Absorb (Mar 2011)
#msg-61809155 1-Year data for Absorb is very impressive
#msg-58615702 EU approves first bioresorbable stent


Diagnostics business
#msg-40949294 Cancer-biomarker collaboration with PFE
#msg-39511634 Cancer-biomarker collaboration with GSK
#msg-51547194 FDA approves improved HIV diagnostic


Corporate, legal, and miscellaneous
#msg-60237946 ABT prevails in Humira litigation with JNJ
#msg-58671882 ABT prevails in Humira litigation with Bayer
#msg-61547460 ABT prevails in Norvir litigation with GSK
#msg-57503923 ABT settles DOJ ‘whistleblower’ suit
#msg-54649451 ABT cuts 3,000 Solvay-related jobs
#msg-55325219 ABT withdraws Meridia diet pill
#msg-55347352 Meridia factoids
#msg-44080721 ABT, Teva settle TriCor patent case
#msg-39903651 ABT wins $400M patent settlement from MDT
#msg-37562781 ABT sues JNJ on Simponi patent
#msg-45878816 Litigation vis-à-vis blood glucose monitoring
#msg-31102936 Musings on Norvir (ritonavir) lawsuit